• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies

  • Print
  • Share
  • E-mail

522 Postmarket Surveillance Studies

  • In May 2008, the oversight responsibility of the 522 Postmarket Surveillance Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH). DEPI continues to build the 522 program.
  • The 522 Postmarket Surveillance Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated under section 522 of the Federal Food, Drug and Cosmetic Act. The program helps ensure that well-designed 522 postmarket surveillance (PS) studies are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated internal tracking system that efficiently identifies the reporting status of active 522 PS studies based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all 522 PS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each 522 PS study. The webpage displays general information regarding each study, as well as the overall study status (based on protocol-driven timelines and adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Nathan S. Ivey, PhD
Senior Scientific Project Manager, 522 Postmarket Surveillance (PS) Studies Program
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Phone: (301) 796-7033
Fax: (301) 847-8140
Show All Studies
Suggest Enhancement / Report Issue  Export to ExcelExport to Excel
Most Recent
Plan Version
Study Status
PS060003 Graft Patency and Technical Failure 05/22/2007 Adult: >21 Progress Adequate

Graft Patency and Technical Failure Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6-mo report 05/11/2009 05/07/2009 On Time
1.5-year report 05/11/2010 06/10/2010 Overdue/Received
2-year report 11/10/2010 11/10/2010 On Time
30 month report 05/14/2011 05/16/2011 Overdue/Received
33 month report 08/12/2011 08/16/2011 Overdue/Received
3-year report 11/10/2011 11/10/2011 On Time
39 month report 02/08/2012 02/08/2012 On Time
42 month report 05/14/2012 05/11/2012 On Time
45 month report 08/12/2012 08/13/2012 Overdue/Received
4-year report 11/09/2012 11/08/2012 On Time
51 mth report & report schedule change req 02/08/2013 02/11/2013 Overdue/Received
54 months report 05/10/2013 05/09/2013 On Time
63 month report 02/07/2014 02/07/2014 On Time
69 month report 03/17/2015    

Show All Studies